{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:52:10Z","timestamp":1774713130573,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s13760-018-0883-2","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T02:48:30Z","timestamp":1516848510000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management"],"prefix":"10.1007","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-4757","authenticated-orcid":false,"given":"Brigitte","family":"Decallonne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Bartholom\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Delvaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"D\u2019haeseleer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souraya","family":"El Sankari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierrette","family":"Seeldrayers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Daumerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"883_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","volume":"31","author":"T Berger","year":"2017","unstructured":"Berger T, Elovaara I, Fredrikson S et al (2017) Alemtuzumab use in clinical practice: recommendations from European Multiple Sclerosis Experts. CNS Drugs 31:33\u201350. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0802670","journal-title":"CNS Drugs"},{"key":"883_CR2","unstructured":"EMA\u2014Lemtrada: EPAR\u2014Product Information (2017) \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003718\/human_med_001678.jsp&mid=WC0b01ac058001d124\n                    \n                  . Accessed 20 July 2017"},{"issue":"17","key":"883_CR3","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786\u20131801. \n                    https:\/\/doi.org\/10.1056\/nejmoa0802670","journal-title":"N Engl J Med"},{"key":"883_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, CARE-MS I investigators et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819\u20131828. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"key":"883_CR5","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, CARE-MS II investigators et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829\u20131839. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"883_CR6","unstructured":"Durelli L, De Mercanti SF, Cucci A et al (2016) Alemtuzumab long-lasting immunological effects: a 48\u00a0months follow-up observation. ECTRIMS Online Library, Sep 15, p. 146466"},{"key":"883_CR7","doi-asserted-by":"publisher","first-page":"16414","DOI":"10.3390\/ijms160716414","volume":"16","author":"T Ruck","year":"2015","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth SG (2015) Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 16:16414\u201316439. \n                    https:\/\/doi.org\/10.3390\/ijms160716414","journal-title":"Int J Mol Sci"},{"key":"883_CR8","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1002\/eji.200535075","volume":"35","author":"A Cox","year":"2005","unstructured":"Cox A, Thompson S, Jones J et al (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 35:3332\u20133342. \n                    https:\/\/doi.org\/10.1002\/eji.200535075","journal-title":"Eur J Immunol"},{"key":"883_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K (2017) Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 74:961\u2013969. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2017.0676","journal-title":"JAMA Neurol"},{"key":"883_CR10","unstructured":"C Dayan, A Cuker, C LaGanke, on behalf of the CARE-MS Investigators et al (2016) Autoimmunity in patients treated With Alemtuzumab for relapsing-remitting multiple sclerosis: 5-year follow-up of the CARE-MS studies. ECTRIMS Online Library, Sep 16, p. 147015"},{"key":"883_CR11","unstructured":"Selmaj K, Habek M, Bass A et al (2017) Efficacy and safety of alemtuzumab in patients with RRMSIs durable over 10\u00a0years: follow-up from the CAMMS223 study. Neurology 88(16), Supplement P5.338"},{"key":"883_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","volume":"89","author":"E Havrdova","year":"2017","unstructured":"Havrdova E, Arnold D, Cohen J, Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy et al (2017) Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology 89:1107\u20131116. \n                    https:\/\/doi.org\/10.1212\/wnl.0000000000004313","journal-title":"Neurology"},{"key":"883_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"A Coles","year":"2017","unstructured":"Coles A, Cohen J, Fox E, CARE-MS II and CAMMS03409 Investigators et al (2017) Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology 89:1117\u20131126. \n                    https:\/\/doi.org\/10.1212\/wnl.0000000000004354","journal-title":"Neurology"},{"key":"883_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","volume":"14","author":"A Antonelli","year":"2014","unstructured":"Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P (2014) Autoimmune thyroid disorders. Autoimmun Rev 14:174\u2013180. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2014.10.016","journal-title":"Autoimmun Rev"},{"key":"883_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/1352458514564490","volume":"21","author":"RA Marrie","year":"2015","unstructured":"Marrie RA, Reider N, Cohen J et al (2015) A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler 21:282\u2013293. \n                    https:\/\/doi.org\/10.1177\/1352458514564490","journal-title":"Mult Scler"},{"key":"883_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000356507","volume":"2","author":"SH Pearce","year":"2013","unstructured":"Pearce SH, Brabant G, Duntas LH et al (2013) 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J 2:215\u2013228. \n                    https:\/\/doi.org\/10.1159\/000356507","journal-title":"Eur Thyroid J"},{"key":"883_CR17","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1089\/thy.2012.0205","volume":"22","author":"JR Garber","year":"2013","unstructured":"Garber JR, Cobin RH, Gharib H, American Association Of Clinical Endocrinologists And American Thyroid Association Taskforce On Hypothyroidism In Adults et al (2013) Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22:1200\u20131235. \n                    https:\/\/doi.org\/10.1089\/thy.2012.0205","journal-title":"Thyroid"},{"key":"883_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cei.12980","volume":"189","author":"T Diana","year":"2017","unstructured":"Diana T, Krause J, Olivo PD et al (2017) Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol 189:304\u2013309. \n                    https:\/\/doi.org\/10.1111\/cei.12980","journal-title":"Clin Exp Immunol"},{"key":"883_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000438750","volume":"4","author":"B Biondi","year":"2015","unstructured":"Biondi B, Bartalena L, Cooper DS et al (2015) The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 4:149\u2013163. \n                    https:\/\/doi.org\/10.1159\/000438750","journal-title":"Eur Thyroid J"},{"key":"883_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS et al (2016) 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343\u20131421. \n                    https:\/\/doi.org\/10.1089\/thy.2016.0229","journal-title":"Thyroid"},{"key":"883_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"DS Cooper","year":"2005","unstructured":"Cooper DS (2005) Antithyroid drugs. N Engl J Med 352:905\u2013917. \n                    https:\/\/doi.org\/10.1056\/NEJMra042972","journal-title":"N Engl J Med"},{"key":"883_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, European Group on Graves\u2019 Orbitopathy (EUGOGO) et al (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326. \n                    https:\/\/doi.org\/10.1159\/000443828","journal-title":"Eur Thyroid J"},{"key":"883_CR23","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1056\/NEJMra021194","volume":"348","author":"EN Pearce","year":"2003","unstructured":"Pearce EN, Farwell AP, Braverman LE (2003) Thyroiditis. N Engl J Med 348:2646\u20132655. \n                    https:\/\/doi.org\/10.1056\/NEJMra021194","journal-title":"N Engl J Med"},{"key":"883_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/ncpendmet0846","volume":"4","author":"K Poppe","year":"2008","unstructured":"Poppe K, Velkeniers B, Glinoer D (2008) The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab 4:394\u2013405. \n                    https:\/\/doi.org\/10.1038\/ncpendmet0846","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"883_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2016.0457","volume":"27","author":"EK Alexander","year":"2017","unstructured":"Alexander EK, Pearce EN, Brent GA et al (2017) Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 27:315\u2013389. \n                    https:\/\/doi.org\/10.1089\/thy.2016.0457","journal-title":"Thyroid"},{"key":"883_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1017\/cjn.2015.48","volume":"42","author":"M Mahzari","year":"2015","unstructured":"Mahzari M, Arnaout A, Freedman MS (2015) Alemtuzumab induced thyroid disease in multiple sclerosis: a review and approach to management. Can J Neurol Sci 42:284\u2013291. \n                    https:\/\/doi.org\/10.1017\/cjn.2015.48","journal-title":"Can J Neurol Sci"},{"key":"883_CR27","unstructured":"Habek M, Arnold D, Cohen J et al (2012) Thyroid autoimmunity in comparison of alemtuzumab and Rebif \u00ae efficacy in multiple sclerosis studies I and II. In: Proceedings of the 22nd meeting of the European Neurological Society (ENS), vol 259"},{"key":"883_CR28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, Wing M, Smith S et al (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691\u20131695. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(99)02429-0","journal-title":"Lancet"},{"key":"883_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","volume":"77","author":"M Cossburn","year":"2011","unstructured":"Cossburn M, Pace AA, Jones J et al (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573\u2013579. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e318228bec5","journal-title":"Neurology"},{"key":"883_CR30","unstructured":"Senior PA, Arnold AL, Cohen JA et al (2016) Incidence and timing of thyroid adverse events in patients with RRMS treated with alemtuzumab. Neurology 86(16), Supplement P2.086"},{"key":"883_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/jc.2013-2201","volume":"99","author":"GH Daniels","year":"2014","unstructured":"Daniels GH, Vladic A, Brinar V et al (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80\u201389. \n                    https:\/\/doi.org\/10.1210\/jc.2013-2201","journal-title":"J Clin Endocrinol Metab"},{"key":"883_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/cen.12427","volume":"80","author":"AP Weetman","year":"2014","unstructured":"Weetman AP (2014) Graves\u2019 disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently? Clin Endocrinol 80:629\u2013632. \n                    https:\/\/doi.org\/10.1111\/cen.12427","journal-title":"Clin Endocrinol"},{"key":"883_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00254","author":"M Rotondi","year":"2017","unstructured":"Rotondi M, Molteni M, Leporati P et al (2017) Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol (Lausanne). \n                    https:\/\/doi.org\/10.3389\/fendo.2017.00254","journal-title":"Front Endocrinol (Lausanne)"},{"key":"883_CR34","unstructured":"Singer B, Hartung H, Margolin D et al (2015) Improvements in quality of life are maintained in alemtuzumab-treated RRMS patients who develop autoimmune adverse events: CARE-MS II. In: Annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC)"},{"key":"883_CR35","unstructured":"Ziemssen T, Selmaj K, Havrdova E et al (2015) Quality-of-life improvements with alemtuzumab are maintained in relapsing-remitting multiple sclerosis patients who develop thyroid adverse events in CARE-MS II. In: Meeting of the European Academy of Neurology (EAN)"},{"key":"883_CR36","unstructured":"Vermersch P, Giovannoni G, Cohen J et al (2015) Quality-of-life improvements in patients with active relapsing-remitting multiple sclerosis are not impacted by acute infections after receiving alemtuzumab in CARE-MS II. ECTRIMS Online Library, Oct 9, p. 115894"},{"key":"883_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3803\/EnM.2016.31.2.213","volume":"31","author":"WM Wiersinga","year":"2016","unstructured":"Wiersinga WM (2016) Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul) 31:213\u2013222. \n                    https:\/\/doi.org\/10.3803\/EnM.2016.31.2.213","journal-title":"Endocrinol Metab (Seoul)"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-018-0883-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-018-0883-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-018-0883-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T03:40:12Z","timestamp":1548387612000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-018-0883-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["883"],"URL":"https:\/\/doi.org\/10.1007\/s13760-018-0883-2","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"9 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author B.D. has received a speaker honorarium from Sanofi. Author E.B. has received consultancy honoraria from Biogen, Biologix, Genzyme, Medical Device Works, Merck Serono, Novartis, TEVA; has participated in local and international advisory boards of Biogen, Genzyme, Merck Serono, Novartis; has received travel grants from Bayer, Biogen, Biologix, Novartis. CHU Tivoli, La Louvi\u00e8re, has received research grants from Bayer, Biogen, Genzyme, Merck Serono, Novartis, TEVA. Author V.D. has received research grants from Biogen and Novartis, and has received a speaker honorarium from Biogen. Author S.E. has received travel grants from Bayer Schering, Biogen Idec, Merck-Serono, TEVA, Sanofi, and a consultancy honorarium from Bayer Schering, Merck-Serono, Sanofi. Author P.S. has received consultancy honorarium and travel grants from Biogen, Genzyme, Merck, Novartis, Roche, Schering, Serono and TEVA. Author B.V. has received research and travel grants, and speaker honoraria from Bayer-Schering, Biogen Idec, Sanofi Genzyme, Merck-Serono, Novartis, Roche and TEVA. Author C.D. is a member of the executive committee of the European Group on Graves\u2019 Orbitopathy (EUGOGO). Editorial support was provided by Thomas Savoye, MD, Blue Jibe Medical Affairs, Herent, Belgium. Funding for this editorial support was provided by Sanofi. The manuscript was reviewed by Darren P. Baker PhD, Steve Cavalier MD, Madalina Chirieac MD, Andreas Lysandropoulos MD, Chantal Maertens PharmD PhD, and Isabel Firmino MD of Sanofi as a courtesy, with no obligation on the authors\u2019 part to adapt the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}